Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.

{"article_title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.","author":"Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA","journal_title":"Journal of the American Academy of Dermatology","issn":"1097-6787","isbn":"","publication_date":"2019-04-01","volume":"80","issue":"4","first_page":"1029","page_count":"","accession_number":"30772098","doi":"10.1016\/j.jaad.2018.11.057","publisher":"Mosby","doctype":"Journal Article","subjects":"Biological Products therapeutic use; Dermatologic Agents therapeutic use; Psoriasis drug therapy; Adalimumab therapeutic use; Antibodies, Monoclonal therapeutic use; Antibodies, Monoclonal, Humanized; Biosimilar Pharmaceuticals therapeutic use; Certolizumab Pegol therapeutic use; Drug Therapy, Combination; Etanercept therapeutic use; Evidence-Based Medicine; Humans; Infliximab therapeutic use; Piperidines therapeutic use; Pyrimidines therapeutic use; Pyrroles therapeutic use; Ustekinumab therapeutic use","interest_area":["Dermatology"],"abstract":"Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations based on the available evidence. The treatment of psoriasis with biologic agents will be reviewed, emphasizing treatment recommendations and the role of the dermatologist in monitoring and educating patients regarding benefits as well as associated risks. Copyright \u00a9 2018 American Academy of Dermatology, Inc. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=30772098","isPdfLink":false,"isSAML":true,"an":"30772098","number_other":"","type_pub":"","issn_electronic":"1097-6787","languages":"English","language":"eng","date_entry":"Date Created: 20190218 Date Completed: 20190412 Latest Revision: 20191210","date_update":"20240105","titleSource":"Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2019 Apr; Vol. 80 (4), pp. 1029-1072. Date of Electronic Publication: 2019 Feb 13.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2019-04-01","description":"Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations based on the available evidence. The treatment of psoriasis with biologic agents will be reviewed, emphasizing treatment recommendations and the role of the dermatologist in monitoring and educating patients regarding benefits as well as associated risks.<br \/> (Copyright © 2018 American Academy of Dermatology, Inc. All rights reserved.)","upload_link":"https:\/\/dx.doi.org\/doi:10.1016\/j.jaad.2018.11.057","no_of_pages":"","authored_by":"Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA","additionalInfo":{"Authored_By":"Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA","Journal_Info":"Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE","Publication_Type":"Journal Article; Practice Guideline; Review","Published_Date":"2019-04-01","Source":"Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2019 Apr; Vol. 80 (4), pp. 1029-1072. Date of Electronic Publication: 2019 Feb 13.","Languages":"English","Electronic_ISSN":"1097-6787","MeSH_Terms":"Biological Products\/*therapeutic use , Dermatologic Agents\/*therapeutic use , Psoriasis\/*drug therapy, Adalimumab\/therapeutic use ; Antibodies, Monoclonal\/therapeutic use ; Antibodies, Monoclonal, Humanized ; Biosimilar Pharmaceuticals\/therapeutic use ; Certolizumab Pegol\/therapeutic use ; Drug Therapy, Combination ; Etanercept\/therapeutic use ; Evidence-Based Medicine ; Humans ; Infliximab\/therapeutic use ; Piperidines\/therapeutic use ; Pyrimidines\/therapeutic use ; Pyrroles\/therapeutic use ; Ustekinumab\/therapeutic use","Subjects":"Adalimumab therapeutic use, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Biosimilar Pharmaceuticals therapeutic use, Certolizumab Pegol therapeutic use, Drug Therapy, Combination, Etanercept therapeutic use, Evidence-Based Medicine, Humans, Infliximab therapeutic use, Piperidines therapeutic use, Pyrimidines therapeutic use, Pyrroles therapeutic use, Ustekinumab therapeutic use, Biological Products therapeutic use, Dermatologic Agents therapeutic use, Psoriasis drug therapy","Title_Abbreviations":"Journal of the American Academy of Dermatology","Volume":"80"},"header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"30772098","RelevancyScore":"762","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"762.292846679688"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=30772098&authtype=shib&custid=ns346513&group=main&profile=eds"}